GlassScriptPhysician profile
Nicholas Byron Touchstone
NPI 1194554402
$4,050.42
in general payments reported to CMS, 2019-2025
17 companies · $4,050 in 2025
The $4,050 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $4,050.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,044 · Education: $6.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,043.62 |
| Education | $6.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $758.61 | 2025 | |
| Alkermes, INC. | $533.60 | 2025 | Aristada, Lybalvi |
| Teva Pharmaceuticals USA, INC. | $519.03 | 2025 | Austedo Xr, Uzedy |
| E.R. Squibb & Sons, L.L.C. | $489.87 | 2025 | Cobenfy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $373.00 | 2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $351.36 | 2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Abbvie INC. | $254.74 | 2025 | |
| Vanda Pharmaceuticals INC. | $223.50 | 2025 | Fanapt |
| Lundbeck LLC | $157.14 | 2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $139.20 | 2025 | Spravato, Invega Trinza, Invega Sustenna |
| Takeda Pharmaceuticals U.S.A., INC. | $72.78 | 2025 | Trintellix |
| Corium, LLC | $49.42 | 2025 | Azstarys |
| Axsome Therapeutics, INC. | $43.81 | 2025 | Auvelity |
| Acadia Pharmaceuticals INC | $25.50 | 2025 | Daybue |
| Supernus Pharmaceuticals, INC. | $21.20 | 2025 | Qelbree |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sage Therapeutics, LLC | $21.20 | 2025 | Zurzuvae |
| Tris Pharma INC | $16.46 | 2025 | Dyanavel Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Touchstone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.